Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) EBT Margin (2016 - 2025)

Voyager Therapeutics' EBT Margin history spans 11 years, with the latest figure at 178.78% for Q4 2025.

  • For Q4 2025, EBT Margin rose 36125.0% year-over-year to 178.78%; the TTM value through Dec 2025 reached 296.17%, down 17571.0%, while the annual FY2025 figure was 296.17%, 21575.0% down from the prior year.
  • EBT Margin for Q4 2025 was 178.78% at Voyager Therapeutics, up from 208.49% in the prior quarter.
  • Across five years, EBT Margin topped out at 1523.23% in Q4 2022 and bottomed at 3239.97% in Q1 2022.
  • The 5-year median for EBT Margin is 365.28% (2021), against an average of 593.68%.
  • The largest annual shift saw EBT Margin plummeted -284665bps in 2022 before it soared 332287bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 18.02% in 2021, then surged by 8353bps to 1523.23% in 2022, then plummeted by -96bps to 63.53% in 2023, then plummeted by -950bps to 540.03% in 2024, then soared by 67bps to 178.78% in 2025.
  • Per Business Quant, the three most recent readings for VYGR's EBT Margin are 178.78% (Q4 2025), 208.49% (Q3 2025), and 641.67% (Q2 2025).